FDA Clearance Tracker · K170005
FLEX Monoclonal Mouse Anti-Human Progesterone Receptor, Clone PgR 1294, Ready-to-Use (Dako Omnis)
Last checked: Nov 20, 2026Latest source record: Dec 21, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Dec 21, 2017
Substantially Equivalent
Time to decision
352 days
Received Jan 3, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K170005
- Device name
- FLEX Monoclonal Mouse Anti-Human Progesterone Receptor, Clone PgR 1294, Ready-to-Use (Dako Omnis)
- Applicant
- Dako Denmark A/S
- Applicant location
- Golstrup, DK
- Received
- Jan 3, 2017
- Decided
- Dec 21, 2017
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 864.1860
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MXZ. The earliest in FDA's data is K990618, decided Jul 23, 1999.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K170005
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Dako Denmark A/S
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K170028 · Decided Dec 21, 2017 · 352 days after receipt
Device type: Immunohistochemistry Antibody Assay, Estrogen Receptor (MYA) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.